Next generation sequencing for diagnosis of central nervous system aspergillosis in liver transplant recipients

Central nervous system Aspergillus fumigatus infection with subarachnoid haemorrhage secondary to hemophagocytic lymphohistiocytosis: a rare case report

BACKGROUND

Secondary central nervous system (CNS) Aspergillus fumigatus infection leading to subarachnoid hemorrhage following the onset of hemophagocytic lymphohistiocytosis (HLH) represents an extremely rare case. We provide a detailed account of the disease course, including laboratory results and brain imaging.

CASE PRESENTATION

A 23-year-old male patient presented with fever and was subsequently diagnosed with HLH after comprehensive examinations. His symptoms were significantly alleviated following treatment with liposomal doxorubicin, etoposide, and methylprednisolone. Three months later, the patient returned with headaches. After completing brain MRI and cerebrospinal fluid next generation sequencing (NGS), he was diagnosed with CNS Aspergillus fumigatus infection. Antifungal treatments including caspofungin, voriconazole, and amphotericin B were administered sequentially. Various indicators were dynamically monitored throughout the course, including cerebrospinal fluid NGS. Four months after the diagnosis of CNS Aspergillus fumigatus infection, the patient suddenly developed subarachnoid hemorrhage, and deceased one month later.

CONCLUSIONS

Patients with HLH on immunosuppressive therapy may be at increased risk of invasive fungal infections, including CNS Aspergillus fumigatus, and close follow-up is necessary. Early completion of cerebrospinal fluid NGS in patients suspected of having concurrent CNS Aspergillus fumigatus infection has positive significance for diagnosis and treatment. Aggressive treatment also plays a significant role in prolonging life expectancy.

Symptomatic central nervous system infections in kidney transplant recipients: a 20-years multicenter observational study

BACKGROUND

Central nervous system (CNS) infections in kidney transplant recipients (KTRs) remain poorly characterized, with current evidence largely derived from isolated case reports over the past two decades. This multicenter study aims to systematically delineate the epidemiology, clinical profiles, and outcomes of CNS infections in a large KTR cohort.

METHODS

We conducted a retrospective analysis of 3,602 KTRs across three transplant centers in China (May 2004-July 2024). CNS infections were defined by: 1) neurological symptoms/signs, and 2) microbiological confirmation via cerebrospinal fluid (CSF) analysis, including metagenomic next-generation sequencing (mNGS) and routine microbiologic testing (bacterial and fungal cultures).

RESULTS

CNS infections were diagnosed in 0.53% of KTRs (19/3602), with symptom onset occurring 2-121 months post-transplantation. Etiologies included bacterial (47%, 9/19), viral (32%, 6/19), and fungal (21%, 4/19) pathogens. Notably, 79% of cases (15/19) were exclusively identified by mNGS, whereas conventional cultures failed detection. Presenting symptoms included headache (79%) and altered mental status (42%). Mortality reached 42% (8/19) within 9-22 days of diagnosis; among survivors, 73% (8/11) exhibited neurological sequelae.

CONCLUSIONS

CNS infections in KTRs are rare but characterized by rapid progression and high fatality rate. While the risk of CNS infections persists throughout the post-transplant period, 1-6 months after transplantation is a higher-incidence period of CNS infections. KTRs with neurological symptoms (particularly headache and elevated CSF pressure) should undergo CSF mNGS which is critical in diagnosing such infections.

A case report of diagnosis and dynamic monitoring of Listeria monocytogenes meningitis with NGS

Listeria monocytogenes (LM) infections of the central nervous system are deadly and have vague symptoms. Traditional cerebro spinal fluid culture has a low positive rate, and because antibiotic use is common following therapy, it is more challenging to assess the response from pathogen content. In this case, a 66-year-old man who had a fever, a headache, and vomit was admitted to the hospital. He had diabetes, decline in thyroid function, and a history of pituitary tumor removal surgery. His initial treatment with ribavirin, ceftriaxone antibiotic, and moxifloxacin did not go well. Using two etiological tests (culture and metagenomic next-generation sequencing [mNGS]), his cerebrospinal fluid tested positively for LM. Ampicillin-sulbactam and meropenem were used as treatments once LM meningitis was identified. After treatment, his cerebrospinal fluid was assessed once more. Culture: negative; targeted next-generation sequencing (tNGS): positive and shows changes in the copy number of the LM. After 44 days of treatment, the patient finally stopped taking antibiotics, and the prognosis was good. Our study showed that mNGS and tNGS, as novel approaches for pathogen detection, are capable of identifying pathogens quickly, sensitively, and accurately, especially when there are few infections present (such as after antibiotic treatment). The two methods can be a powerful assistance for helping clinicians to choose the best course of action.

A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients

The last decade has seen an explosion of advanced assays for the diagnosis of infectious diseases, yet evidence-based recommendations to inform their optimal use in the care of transplant recipients are lacking. A consensus conference sponsored by the American Society of Transplantation (AST) was convened on December 7, 2021, to define the utility of novel infectious disease diagnostics in organ transplant recipients. The conference represented a collaborative effort by experts in transplant infectious diseases, diagnostic stewardship, and clinical microbiology from centers across North America to evaluate current uses, unmet needs, and future directions for assays in 5 categories including (1) multiplex molecular assays, (2) rapid antimicrobial resistance detection methods, (3) pathogen-specific T-cell reactivity assays, (4) next-generation sequencing assays, and (5) mass spectrometry-based assays. Participants reviewed and appraised available literature, determined assay advantages and limitations, developed best practice guidance largely based on expert opinion for clinical use, and identified areas of future investigation in the setting of transplantation. In addition, attendees emphasized the need for well-designed studies to generate high-quality evidence needed to guide care, identified regulatory and financial barriers, and discussed the role of regulatory agencies in facilitating research and implementation of these assays. Findings and consensus statements are presented.